At-home COVID-19 treatments, especially Pfizer’s Paxlovid, are seen as possible game-changers for the pandemic. The emergency use authorization comes as the U.S. sees a surge in new COVID-19 cases and hospitalizations largely driven by the Omicron variant.
Driving the news: Pfizer released new data last week confirming Paxlovid reduced the risk of hospitalization or death by 89% in high-risk adults, Axios’ Tina Reed reports.
An interim analysis of a second study of the pill that has so far shown a 70% reduction in hospitalization among standard-risk adults, Pfizer said.
Pfizer also believes the Paxlovid treatment will work well against the Omicron variant because of the way the drug works.
Join the Conversation
VIP members get the ability to comment on articles.